Trial
NCT02901548
Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
AstraZeneca
Condition
Carcinoma in Situ of Bladder
Intervention
Durvalumab
Why stopped
Study closed early due to futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-07-29